DK0738390T3 - Surrogater for targetmolekyler og forbedrede referencepaneler - Google Patents

Surrogater for targetmolekyler og forbedrede referencepaneler

Info

Publication number
DK0738390T3
DK0738390T3 DK95906754T DK95906754T DK0738390T3 DK 0738390 T3 DK0738390 T3 DK 0738390T3 DK 95906754 T DK95906754 T DK 95906754T DK 95906754 T DK95906754 T DK 95906754T DK 0738390 T3 DK0738390 T3 DK 0738390T3
Authority
DK
Denmark
Prior art keywords
reactivity
panels
receptor
panel
members
Prior art date
Application number
DK95906754T
Other languages
English (en)
Inventor
Lawrence M Kauvar
Hugo O Villar
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/177,673 external-priority patent/US5587293A/en
Application filed by Telik Inc filed Critical Telik Inc
Application granted granted Critical
Publication of DK0738390T3 publication Critical patent/DK0738390T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Laminated Bodies (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Control Of Driving Devices And Active Controlling Of Vehicle (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
DK95906754T 1994-01-06 1995-01-05 Surrogater for targetmolekyler og forbedrede referencepaneler DK0738390T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/177,673 US5587293A (en) 1994-01-06 1994-01-06 Method to identify binding partners
US08/308,813 US5798275A (en) 1994-01-06 1994-09-19 Profiling reference panel enriched by non-IG proteins
PCT/US1995/000081 WO1995018969A1 (en) 1994-01-06 1995-01-05 Surrogates for targets and improved reference panels

Publications (1)

Publication Number Publication Date
DK0738390T3 true DK0738390T3 (da) 2003-07-21

Family

ID=26873529

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95906754T DK0738390T3 (da) 1994-01-06 1995-01-05 Surrogater for targetmolekyler og forbedrede referencepaneler
DK02009879T DK1235072T3 (da) 1994-01-06 1995-01-05 Surrogater for målmolekyler og forbedrede referencefelter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02009879T DK1235072T3 (da) 1994-01-06 1995-01-05 Surrogater for målmolekyler og forbedrede referencefelter

Country Status (11)

Country Link
US (1) US5741653A (da)
EP (1) EP0738390B1 (da)
JP (1) JPH09507300A (da)
AT (2) ATE236401T1 (da)
AU (1) AU700497B2 (da)
CA (1) CA2178096C (da)
DE (2) DE69530179T2 (da)
DK (2) DK0738390T3 (da)
ES (2) ES2196056T3 (da)
PT (1) PT738390E (da)
WO (1) WO1995018969A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
AU5902098A (en) * 1997-01-03 1998-07-31 Terrapin Technologies, Inc. Method to classify gene products
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
KR100406310B1 (ko) 1997-11-12 2003-11-19 3-디멘져널 파마슈티칼즈 인코오포레이티드 게놈 접근법을 사용하여 동정된 단백질의 아직 확인되지 않은 하나 이상의 생물학적 기능을 확인하는 고처리량 방법
WO1999031267A1 (en) * 1997-12-18 1999-06-24 Sepracor Inc. Methods for the simultaneous identification of novel biological targets and lead structures for drug development
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6643591B1 (en) 1998-08-05 2003-11-04 University Of Pittsburgh Use of computational and experimental data to model organic compound reactivity in cytochrome P450 mediated reactions and to optimize the design of pharmaceuticals
US6625547B1 (en) 1998-08-05 2003-09-23 Washington State University Research Foundation Relative rates of cytochrome p450 metabolism
US20040224338A1 (en) * 1998-08-12 2004-11-11 Zycos Inc., A Delaware Corporation Profiling and cataloging expressed protein tags
CA2339817A1 (en) * 1998-08-12 2000-02-24 Zycos Inc. Profiling and cataloging expressed protein tags
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6569631B1 (en) 1998-11-12 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
EP3712897A1 (en) * 2019-03-22 2020-09-23 Tata Consultancy Services Limited Automated prediction of biological response of chemical compounds based on chemical information

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
IE81146B1 (en) * 1987-10-13 2000-05-03 Terrapin Tech Inc Method to produce immunodiagnostic reagents
US5300425A (en) * 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5217869A (en) * 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US4963263A (en) * 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5338659A (en) * 1991-04-02 1994-08-16 Terrapin Technologies, Inc. Method for determining analyte concentration by cross-reactivity profiling
US5340474A (en) * 1988-03-24 1994-08-23 Terrapin Technologies, Inc. Panels of analyte-binding ligands
HUT65361A (en) * 1989-12-29 1994-05-02 Univ Technologies Int Method for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
KR930701975A (ko) * 1990-11-09 1993-09-08 제랄드 에프. 버크 항체 탐지를 위한 검사 시스템의 민감성 그리고/혹은 특이성을 결정하는 방법

Also Published As

Publication number Publication date
AU700497B2 (en) 1999-01-07
DE69530179D1 (de) 2003-05-08
CA2178096C (en) 2004-03-09
AU1522195A (en) 1995-08-01
DE69530179T2 (de) 2004-04-08
ATE236401T1 (de) 2003-04-15
EP0738390B1 (en) 2003-04-02
ATE359509T1 (de) 2007-05-15
CA2178096A1 (en) 1995-07-13
ES2196056T3 (es) 2003-12-16
ES2284743T3 (es) 2007-11-16
WO1995018969A1 (en) 1995-07-13
PT738390E (pt) 2003-07-31
JPH09507300A (ja) 1997-07-22
DE69535463D1 (de) 2007-05-24
DK1235072T3 (da) 2007-07-16
US5741653A (en) 1998-04-21
EP0738390A1 (en) 1996-10-23
DE69535463T2 (de) 2008-01-03

Similar Documents

Publication Publication Date Title
DK0738390T3 (da) Surrogater for targetmolekyler og forbedrede referencepaneler
Andrew et al. Fragmentation of immunoglobulin G
ATE473754T1 (de) Verfahren zur manipulation der zelldifferenzierung
BR9508417A (pt) Acido nucléico isolado cdna isolado proteina isolada vetor de expressão processo para detectar câncer e pré-câncer de pulmão processo para selecionar especimes humanas para proteina hcaviii processo para testar amostra de célula humana anticorpo e composição terapêutica
DE69321218D1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
DK0749325T3 (da) Bispecifikke molekyler med klinisk anvendelse
ATE267394T1 (de) Nachweis der krankheitsbedingten konformation eines proteins
ATE113962T1 (de) Von polypeptiden induzierte monoklonale antikörper gegen oncoproteine.
DE59814441D1 (de) Verwendung von kontrollflächen zur detektion von störproben in einem nachweisverfahren
BR9106217A (pt) Processo para a analise de uma amostra de gas,disposicao de analise,empregos disto e instalacao de teste com a citada disposicao
DK159826C (da) Monoklonalt antistof af typen igg1, og fremgangsmaade til fremstilling deraf, fremgangsmaade til bestemmelse af hba1c samt diagnostisk kit til brug derved
Kakehi et al. Capillary electrophoresis of sialic acid-containing glycoprotein. Effect of the heterogeneity of carbohydrate chains on glycoform separation using an α1-acid glycoprotein as a model
Segura et al. Procedures for monitoring recombinant erythropoietin and analogues in doping control
Righetti et al. The proteome: anno Domini 2002
DK1117685T3 (da) Behandling af inflammatorisk sygdom
CN105277712A (zh) 一种鉴定赖氨酸ε-氨基侧链单甲基化修饰的方法
DE69018968D1 (de) BLUTGERINNUNGSFAKTOR BETA XIIa MONOKLONALE ANTIKÖRPER UND IMMUNANALYSE.
DK26587A (da) Monoklonalt antistof, maalemetode for glucosyleret protein ved anvendelse af det monoklonale antistofog kit omfattende dette
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
SE0003566D0 (sv) A method for the quantitative determination of one or more compounds
DK0789844T3 (da) Anvendelse af et BMP-proteinreceptor-kompleks til screening for aktive stoffer i knoglemetabolisme og celler, der er cotransficieret med en type II-BMP-receptor og en type I-BMP-receptor
Gooderham In situ peptide mapping of proteins following polyacrylamide gel electrophoresis
ATE162224T1 (de) Crf bindungsproteine
DK162726C (da) Fremgangsmaade til eliminering af falsk positive resultater ved bestemmelse af atl virus-antistof og reagens dertil
Murthy Identification of false-positive CK-MB activity in an elderly patient